UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

European journal of cancer (1990), 2008-04, Vol.44 (6), p.781-790

2008

Volltextzugriff (PDF)

Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis

Annals of surgery, 2016-06, Vol.263 (6), p.1188-1198

2016

Volltextzugriff (PDF)

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply

JAMA oncology, 2024-04, Vol.10 (4), p.537

2024

Volltextzugriff (PDF)

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

The lancet oncology, 2011-11, Vol.12 (12), p.1101

2011

Volltextzugriff (PDF)

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.441-451

2012

Volltextzugriff (PDF)

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2772-2779

2015

Volltextzugriff (PDF)

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

The New England journal of medicine, 2009-08, Vol.361 (8), p.766-776

2009

Volltextzugriff (PDF)

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00

Clinical cancer research, 2023-12, Vol.29 (23), p.4908

2023

Volltextzugriff (PDF)

International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland

Breast cancer (Tokyo, Japan), 2001, Vol.8 (4), p.294-297

Thuerlimann, B

2001

Volltextzugriff (PDF)

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3440-3441

2013

Volltextzugriff (PDF)

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

The lancet oncology, 2014-02, Vol.15 (2), p.156-163

2014

Volltextzugriff (PDF)

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort

Scientific reports, 2019-09, Vol.9 (1), p.13534-11, Article 13534

2019

Volltextzugriff (PDF)

Chemotherapy regimens in early breast cancer: major controversies and future outlook

Expert review of anticancer therapy, 2013-02, Vol.13 (2), p.165-178

2013

Volltextzugriff (PDF)

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Journal of clinical oncology, 2007-02, Vol.25 (5), p.486-492

2007

Volltextzugriff (PDF)

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer

Breast (Edinburgh), 2020-06, Vol.51, p.120-126

2020

Volltextzugriff (PDF)

Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials

Journal of clinical oncology, 2008-06, Vol.26 (18), p.3006-3014

2008

Volltextzugriff (PDF)

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3846-3852

2007

Volltextzugriff (PDF)

Abstract OT-23-02: Volumetric analysis of the pectoralis major muscle as preoperative tool to select patients undergoing pre-pectoral versus sub-pectoral implant based breast reconstruction after risk reducing mastectomy

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-23-02-OT-23-02

2021

Volltextzugriff (PDF)

A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction

British journal of cancer, 2016-06, Vol.115 (1), p.80-84

2016

Volltextzugriff (PDF)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

Breast cancer research and treatment, 2007-10, Vol.105 Suppl 1 (S1), p.55-66

2007

Volltextzugriff (PDF)

40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland

BMC cancer, 2015-10, Vol.15 (1), p.666-666, Article 666

2015

Volltextzugriff (PDF)

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1117-1124

2011

Volltextzugriff (PDF)

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3967-3975

2012

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(87)
Tagungsberichte
(1)

Sprache

Englisch
(88)
Japanisch
(11)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Life Sciences & Biomedicine
(77)
Oncology
(74)
Humans
(72)
Female
(65)
Breast Cancer
(48)
Breast Neoplasms - Drug Therapy
(45)
Middle Aged
(41)
Tumors
(34)
Aged
(33)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Antineoplastic Agents, Hormonal - Therapeutic Use
(25)
Chemotherapy, Adjuvant
(25)
Gynecology. Andrology. Obstetrics
(25)
Adult
(24)
Breast Neoplasms - Pathology
(24)
Mammary Gland Diseases
(24)
Treatment Outcome
(21)
Disease-Free Survival
(20)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00

International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort

Chemotherapy regimens in early breast cancer: major controversies and future outlook

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer

Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Abstract OT-23-02: Volumetric analysis of the pectoralis major muscle as preoperative tool to select patients undergoing pre-pectoral versus sub-pectoral implant based breast reconstruction after risk reducing mastectomy

A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial

Suchergebnisse filtern